Stifel raised the firm’s price target on Edwards Lifesciences (EW) to $100 from $95 and keeps a Buy rating on the shares after having attended Edwards’ annual investor day meeting. The firm, which says initial 2026 guidance “looks like a solid starting point,” left the meeting feeling positive about Edwards’ 2026 outlook and long-term set-up, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $89 from $84 at Canaccord
- Edwards Lifesciences price target raised to $96 from $95 at Wells Fargo
- Edwards Lifesciences price target raised to $103 from $100 at BTIG
- Edwards Lifesciences: Strategic Initiatives and Promising Developments Drive Raised Price Target
- Edwards Lifesciences: A Strong Growth Opportunity in Medtech with Expanding Market Potential and Robust Product Portfolio